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Abbreviations 
ASMD: absolute standardized mean difference 
BITA: bilateral internal thoracic artery 
BMI: body mass index 
CCS: Scandinavian cardiovascular Society 
COPD: chronic obstructive pulmonary disease 
CVA: cerebrovascular accident 
DM: diabetes mellitus 
EES: effective sample size 
IABP: intra-aortic balloon pump 
MA: multiple arteries 
MI: myocardial infarction 
NYHA: New York Heart Association 
ONCAB: on-pump coronary artery bypass 
OPCAB: off-pump coronary artery bypass 
PCI: percutaneous coronary intervention 
PVD: peripheral vascular disease 
RA: radial artery 
RRT: renal replacement therapy 
SA: single Artery 
SVG: saphenous vein graft 
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Central message 
Multi-arterial grafting is associated with improved late survival following on- and off-pump 
CABG. Off-pump surgery is associated with similar survival as on-pump surgery, when 
controlling for the extent of arterial revascularization.  
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Perspective statement 
There is growing concern that off-pump coronary artery bypass is associated with reduced 
long-term survival compared with traditional on-pump surgery. However, most available 
comparisons focus on single artery revascularization. We found that off-pump multiple arterial 
grafting is superior to standard on pump single arterial revascularization. Therefore, multiple 
arterial grafting should be the standard strategy in randomized studies comparing off-pump 
with on-pump surgery.   
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Abstract:  
Objective(s): There is growing concern that off-pump coronary artery bypass (OPCAB) is 
associated with reduced long-term survival compared with traditional on-pump coronary artery 
bypass (ONCAB). However most of available comparisons between OPCAB and ONCAB 
focus on single artery (SA) revascularization. We sought to investigate the impact of using 
multiple arterial (MA) conduits in the comparison between OPCAB versus ONCAB by 
performing a single centre long term propensity score base analysis.  
Methods: The study population included 5195 SA-ONCAB, 1208 MA-ONCAB, 4412 SA-
OPCAB and 1818 MA-OPCAB procedures. Late survival was available for all cases (100%). 
Inverse Propensity score weighting and time segmented Cox model were used for multiple 
treatments comparison. 
Results: No significant differences were found between the four groups in terms of 30-day 
mortality, postoperative cerebrovascular accident and renal replacement therapy between the 
four groups. After a mean follow-up time of 8.2±4.7 years, in the PS-weighted sample, survival 
probabilities at 10 years were 74.5±0.4, 79.7±0.4, 73.4±0.5 and 79.0±0.5 in the SA-ONCAB, 
MA-ONCAB, SA-OPCAB and MA-OPCAB groups respectively. Propensity-weighted 
analysis confirmed that MA-OPCAB (HR 0.81;95%CI 0.69-0.98) and MA-ONCAB (HR 
0.81;95%CI 0.65-0.99) were associated with a lower late mortality when compared to standard 
SA-ONCAB.  
Conclusions: OPCAB with multiple arterial grafts is as safe as the conventional ONCAB and 
achieves excellent long term survival rates which are superior to those observed after standard 
SA-ONCAB and comparable to MA-ONCAB.  
 
Keywords: off-pump coronary artery bypass grafting; multiple arterial grafting; 
survival; propensity score  
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There is growing concern that off-pump coronary artery bypass (OPCAB) is associated with 
reduced long-term graft patency of saphenous vein grafts (SVGs) [1-4] and this might translate 
into inferior long-term survival compared with traditional on-pump coronary artery bypass 
(ONCAB) [5]. On the other hand, OPCAB has been associated with arterial graft patency rates 
comparable to those after ONCAB [4].  Technical issues and the learning curve, the 
inflammatory and prothrombotic state in OPCAB patients have been suggested as an 
explanation for the reported inferior graft patency rate. There is also evidence that patients 
operated on-pump have significantly higher saphenous graft mean flow in comparison with 
patients operated off-pump with no difference in these parameters for arterial grafts [6]. As a 
consequence, the use of multiple arterial (MA) grafts including the bilateral internal thoracic 
arteries (BITA) [7,8] and the radial artery (RA) instead of SVGs [7,9] in OPCAB has recently 
gained popularity [10-12]. However most of available comparisons between OPCAB and 
ONCAB focus on single artery (SA) revascularization [13-18]. We sought to investigate the 
impact of using multiple arterial conduits in the comparison between OPCAB versus ONCAB 
by performing a single centre long term propensity score base comparison. We also 
investigated the effects of incomplete revascularization following each of the treatment 
strategies. 
Methods 
The study was conducted in accordance with the principles of the Declaration of Helsinki. The 
local audit committee approved the study, and the requirement for individual patient consent 
was waived. We retrospectively analysed prospectively collected data from The National 
Institute for Cardiovascular Outcomes Research (NICOR) NACSA registry on 1 June 2015 for 
all isolated first time CABG procedures performed at the Bristol Heart Institute, Bristol United 
Kingdom from 1996 to April 2015.  Reproducible cleaning algorithms were applied to the 
database, which are regularly updated as required. Briefly, duplicate records and non-adult 
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cardiac surgery entries were removed; transcriptional discrepancies harmonized; and clinical 
conflicts and extreme values corrected or removed. The data are returned regularly to the local 
units for validation.  
Further details and definition of variables are available at 
http://www.ucl.ac.uk/nicor/audits/adultcardiac/datasets. Among 15119 isolated first time 
CABG cases performed at our institution during the study period, we selected subjects who 
met the following criteria: first time isolated CABG; multivessel coronary disease and/or left 
main disease; requiring at least 2 grafts; CABG performed by using the following four 
strategies: on pump single left internal thoracic artery grafting (LITA) plus additional SVGs 
(SA-ONCAB, reference group);  on pump multiple arterial grafting (by using LITA plus RITA 
and/or RA) with or without additional SVGs (MA-ONCAB); off pump single internal thoracic 
artery grafting plus additional SVGs (SA-OPCAB); off pump multiple arterial grafting (by 
using LITA plus RITA and/or RA) with or without additional SVGs (MA-OPCAB, video 1). 
In the present series, the surgical strategy was based on individual surgeon preference and 
expertise. In the present series, the RA was considered only in case of target stenosis ≥75% 
and it was used a free graft proximally connected to the ascending aorta. The internal thoracic 
artery was used as a pedicle graft that remained proximally connected to its respective 
subclavian artery (in situ) or as a free graft proximally connected to other internal thoracic 
artery.  
Pre-treatment variables and study end-points  
The effect of MA conduits and OPCAB was adjusted for the following pre-treatment variables 
including: age, gender, body mass index (BMI); Canadian Cardiovascular Society (CCS) grade 
III or IV; New York Heart Association grade III or IV; previous myocardial infarction (MI) 
and MI within 30 days, previous percutaneous coronary intervention (PCI); diabetes mellitus 
(DM) on oral treatment or on insulin (DM-I); chronic obstructive pulmonary disease (COPD); 
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current smoking; serum creatinine ≥200 mmol/l, previous cerebrovascular accident (CVA); 
peripheral vascular disease (PVD); preoperative atrial fibrillation (AF); left main disease 
(LMD); 3-vessel disease (TVD); left ventricular ejection fraction (LVEF) between 30% and 
49%; LVEF less than 30%; non elective admissiom, emergent/salvage operation; cardiogenic 
shock; preoperative intra-aortic balloon pump (IABP) and year of surgery. Logistic 
EuroSCORE was used as measure of overall risk profile but not included in the propensity 
score model.   
The short-term outcomes investigated were: the incidence of re-exploration for bleeding, need 
for sternal wound reconstruction, postoperative CVA (defined as any confirmed neurologic 
deficit of abrupt onset that did not resolve within 24 hours), postoperative renal replacement 
therapy (RRT), need for postoperative IABP and early mortality (within 30 days). We also 
reported as short term outcomes, incomplete revascularization (IR), defined as at least one 
diseased primary arterial territory not grafted. Long-term outcome investigated was all-cause 
late mortality. Information about post-discharge mortality tracking was available for all 
patients (100%) and was obtained by linking the institutional database with the National 
General Register Office.  
Statistical analysis 
For baseline characteristics, variables are summarised as mean for continuous variables and 
percentage for categorical variables. The chi squared test was used to test unadjusted 
association between treatment variable and outcomes. Multiple imputation (m=3) was used to 
address missing data (165 patients). Rubin’s method [19] was used to combine results from 
each of m imputed data sets.   
Inverse probability (propensity score) of treatment weighting (IPSW) for modelling causal 
effects was used for multiple treatments comparison [20]. A generalised boosted model was 
implemented to estimate multinomial propensity scores (PS) adjusting for  pre-treatment 
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covariates, and the propensity score was assumed as the probability that an individual with pre-
treatment characteristics X receives treatment t (twang R package).The average treatment 
effect on the population (ATE) was used to answer the question of how, on average, the 
outcome of interest would change if everyone in the population of interest had been assigned 
to a particular treatment relative to if they had all received another single treatment. To estimate 
the ATE, we gave treated patients weight wi = 1/(1 – p(xi)), where p(xi) is the propensity score, 
and reference patients wi = 1/p(xi). SA-ONCAB was considered as the reference group in all 
comparisons. The absolute standardised mean difference (ASMD) was used as a balance metric 
to summarize the difference between two univariate distributions of a single pre-treatment 
variable. A value ≥0.20 was considered as an indicator of imbalance [21]. Although all subjects 
are retained using IPSW, weighted means can have greater sampling variance than unweighted 
means from a sample of equal size. To account for such observation, we calculated the effective 
sample size (ESS) which gives an estimate of the number of comparison participants that are 
comparable to the treatment group [20]. We then estimated the treatment effect estimates by 
using weighted logistic regression models for postoperative complications and weighted time-
segmented Cox models for early (within 30 days) and late (beyond 30 days) mortality. These 
models contained only a treatment indicator. Lastly, we estimated the treatment effect within 
subgroups according to the presence of incomplete revascularization, total arterial 
revascularization and era of surgery. R version 3.1.2 (2014-10-31) was used for all statistical.  
Results 
Study population 
The study population included 5195 SA-ONCABs, 1208 MA-ONCABs, 4412 SA-OPCAB and 
1818 MA-OPCABs (Figure 1). Preoperative variables distribution in the four groups is 
summarized in Table 1.  In the unweighted population, SA-ONCAB and SA-OPCAB groups 
tended to present a higher burden of comorbidities when compared to MA-ONCAB and MA-
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OPCAB. In particular SA-ONCAB and SA-OPCAB patients were more likely to older, female, 
and present NYHA III-IV functional class, COPD and LVEF≤30%. SA-ONCAB cases were 
more likely to have 3-vessel disease when compared to the other groups (Supplementary Table 
1). After PS-weighting the four groups were comparable for all pre-treatment variables 
(ASMD<0.20, Table 2, Supplementary Table 2, Supplementary Figure 1). Although the 
original MA-ONCAB and MA-OPCAB groups had 1208 and 1818 cases respectively, the 
propensity score estimates effectively utilized only 388 and 739 of the comparison cases with 
a significant loss of sample size. This indicates that many of the original cases were not useful 
for isolating the treatment effect. 
 
Intraoperative data 
Intraoperative data are summarized in Table 3. Among patients receiving MA conduits, BITA 
was used more often during ONCAB whilst RA was used more often during OPCAB. However 
the overall rate of total arterial revascularization was comparable between ONCAB and 
OPCAB. Overall, numbers of grafts were lower among OPCAB cases. Both circumflex artery 
and right coronary artery territories were less likely to be grafted during OPCAB, but this was 
more evident among SA-OPCAB cases. The overall incidence of IR was higher among 
OPCAB in particular after SA-OPCAB. However, the majority of MA-OPCAB cases received 
complete revascularization (91.3%) and the absolute increase in IR rate in the MA-OPCAB 
group was marginal when compared to SA-ONCAB (+2.9%) and MA-ONCAB (+3.5%). 
Short term outcomes 
Observed 30-days mortality and rate of postoperative complications are summarized in Table 
4. Unadjusted treatment effect estimates on outcomes of interest are summarized in Table 5. 
Overall crude 30-day mortality rate was 152(1.2%) with a significant trend towards a reduced 
mortality with MA-ONCAB and MA-OPCAB when compared to standard SA-ONCAB. The 
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crude incidences of postoperative CVA, IABP and RRT were significantly lower in MA-
OPCAB. SA-OPCAB and MA-OPCAB were associated with a reduced rate of re-exploration 
for bleeding. However, this observed trend towards a reduced morbidity and early mortality in 
the MA-OPCAB group was correlated to the higher burden of comorbidities observed in SA-
ONCAB and SA-OPCAB groups rather than a real treatment effect. In fact, after PS-weighting 
(Table 5), no significant differences were found between the four groups in terms of 30-day 
mortality, postoperative CVA and RRT between the four groups. However, OPCAB still 
remained associated with a trend towards reduced incidence of postoperative IABP and re-
exploration for bleeding. In the PS-weighted analysis OPCAB remained associated with a 2-
fold increased risk of incomplete revascularization regardless of the use of multiple arterial 
grafts.    
Long term survival   
After a mean follow-up time of 8.2±4.7 years, there were 1583(30%), 195(16%), 1103(25%) 
and 269(15%) deaths in the SA-ONCAB, MA-ONCAB, SA-OPCAB and MA-OPCAB groups 
respectively. In the unweighted sample, survival probabilities at 10 were 72.4±0.7, 89.3±0.9, 
69.7±0.9 and 83.7±0.1 and in the SA-ONCAB, MA-ONCAB, SA-OPCAB and MA-OPCAB 
groups respectively. In the PS-weighted sample, survival probabilities at 10 years were 
74.5±0.4, 79.7±0.4, 73.4±0.5 and 79.0±0.5 in the SA-ONCAB, MA-ONCAB, SA-OPCAB and 
MA-OPCAB groups respectively (Figure 2 left). In the unweighted sample SA-OPCAB was 
associated with a lower survival when compared to the standard SA-ONCAB whilst MA-
ONCAB and MA-OPCAB were associated with better late survival (Table 4). PS-weighted 
analysis (Figure 2 right) confirmed that MA-OPCAB and MA-ONCAB were associated with 
a relative 20% risk reduction in late mortality when compared to standard SA-ONCAB whilst 
PS-weighted SA-OPCAB did not significantly increase the risk of late death (Table 4). When 
the analysis was restricted to subjects who had complete revascularization, MA-OPCAB (adj 
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HR 0.80;95%CI 0.65-0.97; P=0.02) and MA-ONCAB (adj HR 0.80;95%CI0.63-0.99; P=0.04) 
but not SA-OPCAB (adj HR 1.05; 95%CI 0.94     1.17; P=0.39) were associated with a reduced 
risk of late death when compared to SA-ONCAB. On the other hand, among subject with 
incomplete revascularization, we found that neither MA-OPCAB (adj HR 0.95;95%CI 0.62-
1.46; P=0.82) or MA-ONCAB (adj HR 1.06; 0.60-1.90; P=0.83) or SA-OPCAB (adj HR 
1.07;95%CI 0.77-1.48; P=0.69) were associated with better long term survival when compared 
to SA-ONCAB (Supplementary Figure 2). We could not demonstrate a superiority in terms 
of late survival by using total arterial OPCAB (adj HR 0.77; 95%CI 0.60-0.98) instead of 
MA-OPCAB with additional SVGs (adj HR 0.71;9%%CI 0.57-0.89) or by using total 
arterial ONCAB (adj HR 0.84; 95%CI 0.64-1.09) instead of MA-ONCAB with additional 
SVGs (adj HR 0.57;95%CI 0.42-0.78) over the standard SA-ONCAB strategy 
(Supplementary Figure 3). However the incidence of IR among total arterial-OPCAB and 
total arterial-ONCAB was particularly high (20% and 12% respectively) when compared to 
MA-OPCAB with additional SVGs (0%) and MA-ONCAB with additional SVGs (0.4%) and 
this aspect might have caused an underestimation of the effect of total arterial revascularization. 
The effect of era of surgery was also investigated (Supplementary Figure 4). When compared 
to SA-ONCAB, MA-OPCAB was associated with reduced late mortality during the era 1996-
2004 (adj HR 0.83; 95%CI 0.64-0.99) and 2005-2009 (adj HR 0.73;95%CI 0.55-0.96) while 
the two strategies were comparable after 2010 and this is partially explained by the relatively 
short follow-up duration (<5 years). When compared to standard SA-ONCAB, MA-OPCAB 
also did not increase early mortality across eras (1996-2004: HR 0.88;95%CI 0.25- 3.01; after 
2010 MA-OPCAB: HR 0.28; 95%CI 0.03 -2.15 respectively).   
 
Discussion 
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The main finding of the present study is that MA-OPCAB can be performed with a very low 
operative mortality and morbidity. Complete revascularization with MA-OPCAB was achieved 
in the majority of patients (92.3%). MA-OPCAB with complete revascularization was 
associated with excellent long term survival rates which are at least comparable to those 
observed after MA-ONCAB and significantly superior to those observed after SA-ONCAB. 
SA-OPCAB was associated with poorer long term survival when compared to SA-ONCAB 
although this difference was no longer statistically significant after risk adjustment.  Among 
cases with incomplete revascularization we could not identify any difference between ONCAB 
and OPCAB in terms of late survival regardless the use of MA grafts although this analysis 
was largely underpowered. In the present analysis we used all-cause mortality to assess 
treatment effect on long term. All cause-mortality is considered the most robust and unbiased 
index in cardiovascular research because no adjudication is required, thus avoiding inaccurate 
or biased documentation and clinical assessments [22]. The four groups were compared using 
inverse propensity score weighting. One of the advantages of this technique over standard 
pairwise propensity matching is the possibility of simultaneous comparisons between multiple 
treatments. Moreover, all the individuals in the study can be used for the outcomes evaluation 
whilst a large number of subjects may not be used in a propensity matching. 
Whether OPCAB surgery is superior to traditional ONCAB surgery remains one of the most 
controversial areas of cardiac surgery. In North America, OPCAB procedures peaked at 25% 
in 2004 and have declined steadily since that time [23]. Among possible explanations, there is 
growing concern that OPCAB is associated with reduced long-term graft patency thus resulting 
in inferior long-term survival compared with traditional ONCAB as observed by some authors 
[5]. However, meta-analyses of currently available randomized controlled trials on graft 
patency have shown that OPCAB increases the incidence of SVG graft occlusion only but does 
not affect internal thoracic artery and RA graft patency when compared with ONCAB [4]. As 
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a consequence recent reports advocate for a more extensive use of arterial grafts during 
OPCAB in order to improve OPCAB results. Suzuki et al. [10] recently reported on 260 cases 
undergoing OPCAB with SVG and 520 cases of OPCAB with total arterial revascularization 
and total arterial OPCAB was protective in terms of late cardiac events (HR 0.5;95%CI 0.31–
0.84; P=0.007). In a previous study, Kinoshita et al. [11] compared off-pump skeletonized 
single (n=236) versus bilateral (n=300) internal thoracic artery grafting in high risk cases 
(Euroscore≥5). After a mean follow-up of 3.2 years, BITA grafting was significantly associated 
with a lower risk of overall death (hazard ratio, 0.56; 95% CI, 0.32 to 0.87; P=0.009). Navia et 
al. recently compared 1447 OPCAB cases with BITA grafting versus and 253 OPCAB with 
received left internal thoracic artery and radial artery grafting [12].  They found that the two 
strategies where comparable in terms of late mortality (P=0.65) although BITA grafting was 
associated with lower postoperative reintervention/readmission-free survival (P=0.03).  
However, available randomized comparative studies on long term survival after OPCAB versus 
ONCAB included mainly procedure with left internal thoracic artery to left anterior descending 
artery and small number of other arterial grafts [13-18]. Therefore, the impact of multiple 
arterial grafts on long term survival after OPCAB versus ONCAB still needs to be determined. 
To date few studies focused on early outcomes after MA-OPCAB versus MA-ONCAB. 
Kobayashi et al. [24] reported on 167 consecutive unselected patients randomly assigned to 
undergo MA-OPCAB (n=81) or MA-ONCAB (n=86) and they found that the incidence of 
perioperative complications was similar. In the BITA arm of the Arterial revascularization trial 
(ART) [25], OPCAB and ONCAB were found comparable in terms of 1 year outcomes. 
The completeness of revascularization has been a major concern in OPCAB. As OPCAB with 
arterial grafts is thought to be technically demanding, incomplete revascularization might limit 
its benefit on long term survival [26]. In a recently published large series, [25] Omer et al 
reported a 29% rate of IR in 6367 OPCAB cases compared to 11.0% in 34,772 ONCAB cases. 
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However, in the present series, IR rate in the MA-OPCAB group was relatively low and only 
marginally higher than MA-ONCAB (8.7% versus 5.2%). These findings confirmed that 
complete revascularization can be achieved in MA-OPCAB in the majority of cases and this 
conclusion is supported by previous reports. In their randomized trial, Kobayashi et al. [24] 
found that completeness of revascularization (completed grafts/planned grafts) was 98% in 
both MA-OPCAB and MA-ONCAB groups. In the BITA arm of the ART [24], OPCAB and 
ONCAB groups showed comparable number of grafts per patient. Of note, in a recent report 
on the Veterans Affairs Continuous Improvement in Cardiac Surgery Program [26]  involving 
41,139 patients with left main and 3-vessel coronary artery disease, the IR rate among 6367 
OPCAB cases was remarkably high (29%) compared to that observed in 34,772 ONCAB cases 
(11.0%). A possible explanation for the relatively low IR rate observed in our MA-OPCAB 
series is the high OPCAB volume at our centre performed by experienced surgeons during the 
study period. The high OPCAB volume can also partially account for the quasi-equipoise 
between OPCAB and ONCAB in patients receiving a single arterial graft, thus confirming a 
central role of surgeon experience in determining outcomes after myocardial revascularization 
without cardiopulmonary bypass [27].   
Limitations 
Although the data were collected prospectively, the main limitation is the retrospective 
analysis. It is possible that patients receiving MA conduits where younger and healthier. 
Propensity technique can adjust only for measurable and included variables and we cannot 
exclude a selection bias based on non-measurable “eye-ball”. Moreover, we were unable to 
provide specific causes of death (cardiac vs non-cardiac) as well as incidence of major cardiac 
adverse events including myocardial infarction and repeat revascularization and therefore, we 
can only speculate that the mechanism beyond the equipoise between OPCAB and ONCAB on 
long-term survival. Another limitation of this study is that OPCAB was performed by 
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experienced surgeons and the results may not be the same with surgeons in their learning curve 
period or in low volume OPCAB centres. These results might be true only for cardiac surgeons 
and anaesthesiologists who are fully accustomed to OPCAB. Furthermore, patients might have 
been selected for MA grafting OPCAB only when complete revascularization was deemed 
possible. The use of MA grafts has declined in t recent years. In our healthcare system there is 
an increasing demand for reducing resource utilization and this might influence surgeons in 
adopting MA grafting which is more time consuming. It can also be speculated that the use of 
the radial artery was often preferred over a second internal thoracic artery as anticipated to be 
less time consuming and technically demanding.   The decrease in the number of OPCAB 
procedures in recent years in our centre, can be explained with the appointment of two young 
surgeons with no previous training in this technique, the retirement of one of the most senior 
OPCAB surgeon and the part time position of the senior surgeon who first introduced the 
technique. 
In conclusion, multi-arterial grafting was associated with improved late survival following on- 
and off-pump CABG. Off-pump was consistently associated with a lower risk of need for IABP 
postoperatively and re-exploration and it was associated with similar 10 years survival as on-
pump surgery, when controlling for the extent of arterial revascularization. Complete 
revascularization during OPCAB is achievable in the majority of cases and it should still be 
the main goal while performing OPCAB surgery in order to optimize outcomes after surgical 
revascularization.  
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Table 1. Pre-treatment variables in the unweighted population 
 
SA-ONCAB MA-ONCAB SA-OPCAB MA-OPCAB Max 
ASDM  
N=5194 N=1208 N= 4412 N=1818 
 
 n % n % n % n %  
Age (years, sd) 68±8  57±8  69±9  61±9  121% 
Female  935 18 109 9 838 19 218 12 26% 
CCS III-IV  1610 31 290 24 1324 30 382 21 21% 
NYHA III-IV 2701 52 580 48 1985 45 782 43 18% 
MI within 30days  987 19 145 12 971 22 345 19 26% 
PCI  208 4 36 3 265 6 109 6 15% 
DM orally treated  571 11 72 6 485 11 164 9 18% 
DM on insulin  364 7 60 5 353 8 109 6 12% 
Current smoking  623 12 217 18 529 12 273 15 18% 
Creatinine≥200mmol/l  156 3 12 1 132 3 18 1 16% 
COPD  416 8 36 3 353 8 91 5 2% 
CVA  208 4 36 3 176 4 36 2 11% 
PVD  571 11 72 6 485 11 127 7 15% 
Atrial fibrillation   208 4 24 2 176 4 36 2 8% 
3-vessel disease 4155 80 870 72 3044 69 1218 67 3% 
Left main disease 1299 25 242 20 1279 29 509 28 21% 
LVEF between 30-49%  1195 23 205 17 1015 23 291 16 17% 
LVEF ≤30% 312 6 36 3 221 5 18 1 21% 
Cardiogenic shock  52 1 0 0 0 0 0 0 11% 
Preoperative IABP  104 2 0 0 44 1 0 0 12% 
Non-elective admission  2545 49 507 42 2162 49 745 41 16% 
Emergent/salvage  52 1 0 0 44 1 18 1 1% 
BMI  28±5 
 
28±4 
 
28±4 
 
28±4 
 
19% 
Year of surgery 2004±6 
 
2002±4 
 
2007±4 
 
2006±4 
 
92% 
Logistic Euroscore 4.3±4.8  2.1±2.2  4.5±4.8  2.5±2.8   
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SA: single Artery; MA: multiple arteries; OPCAB: off-pump coronary artery bypass; ONCAB: on-pump coronary artery bypass; NYHA: New York Heart Associatio; CCS: 
Canadian Cardiovascular Society; MI: myocardial infarction; PCI: percutaneous coronary intervention; DM: diabetes mellitus; COPD: chronic obstructive pulmonary disease; 
CVA: cerebrovascular accident;  PVD: peripheral vascular disease; LVEF: left ventricular ejection fraction; IABP: intra-aortic balloon pump; BMI: body mass index; ASMD: 
absolute standardized mean difference 
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Table 2. Pre-treatment variables in the PS-weighted population 
  
SA-ONCAB MA-ONCAB SA-OPCAB MA-OPCAB Max 
ASDM 
  ESS=3972 ESS=388 ESS=2567 ESS=739  
  n % n % n % n %  
Age (years, sd) 66±10   65±10   66±9   65±9   14% 
Female  675 17 58 15 410 16 118 16 6% 
NYHA III-IV  1906 48 186 48 1206 47 339 46 4% 
CCS III-IV  1151 29 116 30 744 29 199 27 8% 
MI within 30 days  794 20 69 18 487 19 147 20 4% 
PCI  198 5 19 5 128 5 44 6 4% 
DM orally treated  397 10 38 10 282 11 73 10 2% 
DM on insulin  278 7 19 5 179 7 44 6 10% 
Current smoking  556 14 46 12 333 13 88 12 5% 
Creatinine≥200mmol/l  79 2 3 1 51 2 7 1 10% 
COPD  278 7 27 7 179 7 44 6 5% 
CVA  158 4 15 4 102 4 14 2 10% 
PVD  397 10 31 8 256 10 59 8 7% 
Atrial fibrillation   119 3 15 4 77 3 22 3 6% 
3-vessel disease 2939 74 279 72 1848 72 524 71 8% 
Left main disease 1032 26 100 26 693 27 192 26 2% 
LVEF between 30-49%  873 22 89 23 539 21 147 20 8% 
LVEF ≤30% 198 5 23 6 102 4 22 3 16% 
Cardiogenic shock  0 0 0 0 0 0 0 0 7% 
Preoperative IABP  39 1 0 0 25 1 7 1 9% 
Non-elective admission  1866 47 182 47 1232 48 332 45 6% 
Emergent/salvage  39 1 3 1 25 1 7 1 6% 
BMI  28±4   28±4   28±4   28±4   8% 
Year of surgery 2005±4   2005±6   2006±6   2005±8   13% 
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Logistic Euroscore 3.9±3.8   3.7±5.9   3.9±3.6   3.6±4.1    
SA: single Artery; MA: multiple arteries; OPCAB: off-pump coronary artery bypass; ONCAB: on-pump coronary artery bypass; EES: effective sample size; NYHA: New 
York Heart Association; CCS: Canadian Cardiovascular Society; MI: myocardial infarction; PCI: percutaneous coronary intervention; DM: diabetes mellitus; COPD: chronic 
obstructive pulmonary disease; CVA: cerebrovascular accident;  PVD: peripheral vascular disease; LVEF: left ventricular ejection fraction; IABP: intra-aortic balloon pump; 
BMI: body mass index; ASMD: absolute standardized mean difference 
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Table 3. Intraoperative data 
             SA-ONCAB 
N=5194 
MA-ONCAB 
N=1208 
SA-OPCAB 
N=4412 
MA-OPCAB 
N=1818 
χ2 P-
value 
  N % n % n % n %  
MA configuration BITA - - 420 34.8 - - 335 18.4 <0.0001 
 RA   617 51.1   1384 76.2  
 BITA+RA   171 14.1   99 5.4  
           
Total arterial Revascularization No   708 58.6   1031 56.7 0.31 
 Yes   500 41.4   787 43.3  
           
Number of grafts   1 1 0.0 1 0.1 0 0.0 0 0.0 <0.0001 
          2 1004 19.3 330 27.3 1662 37.7 645 35.5  
          3 3020 58.1 609 50.4 2383 54.0 913 50.2  
          4 1106 21.3 249 20.6 357 8.1 252 13.9  
          5 62 1.2 19 1.6 9 0.2 8 0.4  
          6 1 0.0 0 0.0 1 0.0 0 0.0  
           
Mean grafts/pt  3.04±0.67 2.96±0.74 2.71± 0.62 2.79±0.68 <0.0001 
           
LAD  territory grafted     No 89 1.7 22 1.8 89 2.0 43 2.4 0.3 
          Yes 5105 98.3 1186 98.2 4323 98.0 1775 97.6  
    
        
 
RCA  territory grafted No 1265 24.4 316 26.2 1406 31.9 609 33.5 <0.0001 
          Yes 3929 75.6 892 73.8 3006 68.1 1209 66.5  
    
        
 
CX territory grafted         No 655 12.6 208 17.2 1031 23.4 323 17.8 <0.0001 
          Yes 4539 87.4 1000 82.8 3381 76.6 1495 82.2  
    
        
 
Diagonal branch grafted     No 3887 74.8 915 75.7 3607 81.8 1428 78.5 <0.0001 
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          Yes 1307 25.2 293 24.3 805 18.2 390 21.5  
    
        
 
Sequential anastomosis No 4956 95.4 1130 93.5 4097 92.9 1694 93.2 <0.0001 
          Yes 238 4.6 78 6.5 315 7.1 124 6.8  
    
        
 
SA: single Artery; MA: multiple arteries; OPCAB: off-pump coronary artery bypass; ONCAB: on-pump coronary artery bypass; BITA: bilateral internal thoracic arteries; 
RA: Radial artery; LAD: left anterior descending artery; RCA: right coronary artery; CX: circumflex artery.   
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Table 4. Incidence of postoperative outcomes  
 
         
    SA-ONCAB 
N=5194 
MA-ONCAB 
N=1208 
SA-OPCAB 
N=4412 
MA-OPCAB 
N=1818 
χ2 
P-value 
  N % n % n % n %  
Mortality within 30 days  No 5125 98.7 1201 99.4 4344 98.5 1810 99.6 0.0005 
        Yes 69 1.3 7 0.6 68 1.5 8 0.4  
             
Postoperative CVA No 5112 98.4 1197 99.1 4348 98.5 1808 99.4 0.005 
        Yes 82 1.6 11 0.9 64 1.5 10 0.6  
             
Postoperative IABP No 5023 96.7 1188 98.3 4318 97.9 1796 98.8 <0.0001 
        Yes 171 3.3 20 1.7 94 2.1 22 1.2  
             
Postoperative RRT No 5075 97.7 1192 98.7 4299 97.4 1799 99.0 0.003 
        Yes 119 2.3 16 1.3 113 2.6 19 1.0  
             
Sternal wound reconstruction No 5157 99.3 1204 99.7 4376 99.2 1808 99.4 0.3 
        Yes 37 0.7 4 0.3 36 0.8 10 0.6  
             
Re-exploration No 5021 96.7 1164 96.4 4312 97.7 1786 98.2 0.0001 
        Yes 173 3.3 44 3.6 100 2.3 32 1.8  
           
IR        No 4888 94.1 1145 94.8 3898 88.3 1659 91.3 <0.0001 
          Yes 306 5.9 63 5.2 514 11.7 159 8.7  
SA: single Artery; MA: multiple arteries; OPCAB: off-pump coronary artery bypass; ONCAB: on-pump coronary artery bypass; CVA: 
cerebrovascular accident; IABP: intra-aortic balloon pump; RRT: renal replacement therapy; IR: incomplete revascularization 
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Table 5. PS-weighted estimates (SA-ONCAB as a reference group; Bold: P<0.05) 
 
         
Treatment 
group 
Crude 
  ES[95%CI] 
crude 
P value 
PS-weighted 
ES[95%CI] 
PS-weighted 
P value 
Mortality within 30 days MA-ONCAB 0.43[0.20-0.94] 0.03 0.96[0.28- 3.22] 0.95 
        SA-OPCAB 1.16[0.83-1.62] 0.38 0.96[0.67-1.39] 0.86 
  MA-OPCAB 0.33[0.16-0.69] 0.03 0.44[0.18-1.08] 0.07 
      
Postoperative CVA MA-ONCAB 0.57[0.30-1.08]     0.08 1.84[ 0.72-4.70] 0.20 
        SA-OPCAB 0.92[0.66-1.28] 0.60 1.08[0.72-1.63] 0.70 
 MA-OPCAB 0.35[0.18-0.67] 0.001 0.90[0.38-2.11] 0.81 
       
Postoperative IABP MA-ONCAB 0.49[0.31-0.79] 0.003 1.67[0.88-3.15] 0.11 
        SA-OPCAB 0.64[0.50-0.83] <0.0001 0.69[0.51-0.92] 0.01 
  MA-OPCAB 0.36[0.23-0.56] <0.0001 0.70[0.41-1.20] 0.20 
      
Postoperative RRT MA-ONCAB 0.57[0.34-0.97] 0.03 1.23[0.55-2.76] 0.61 
        SA-OPCAB 1.12[0.86-1.46] 0.39 1.15[0.86-1.54] 0.34 
 MA-OPCAB 0.45[0.28-0.73] 0.001 0.82[0.41-1.63] 0.57 
       
Sternal wound reconstruction  MA-ONCAB 0.46[0.16-1.30] 0.14 2.33[0.64-8.39] 0.20 
        SA-OPCAB 1.15[0.72-1.82] 0.46 1.10[0.50-2.40] 0.59 
 MA-OPCAB 0.77[0.38-1.55] 0.56 0.87[0.54-1.41] 0.81 
       
Re-exploration  MA-ONCAB 1.10[0.78-1.54] 0.59 1.18[0.68-2.03] 0.55 
        SA-OPCAB 0.67[0.52-0.86] <0.0001 0.66[0.51-0.87] 0.002 
 MA-OPCAB 0.52[0.36-0.76] <0.0001 0.78[0.49-1.24] 0.28 
       
IR MA-ONCAB 0.88[0.66-1.15] 0.36 1.002[0.61-1.65] 0.99 
 SA-OPCAB 2.11[1.82-2.44] <0.0001 2.39[2.01-2.86] <0.0001 
 MA-OPCAB 1.53[1.25-1.86] <0.0001 2.04[1.54-2.68] <0.0001 
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Late mortality (beyond 30 days) MA-ONCAB 0.36[0.31-0.42] <0.0001 0.81[0.649-0.99] 0.04 
 SA-OPCAB 1.14[1.05-1.24] 0.001 1.07[0.96-1.19] 0.20 
 MA-OPCAB 0.56[0.49-0.64] <0.0001 0.81[0.69-0.98] 0.03 
SA: single Artery; MA: multiple arteries; OPCAB: off-pump coronary artery bypass; ONCAB: on-pump coronary artery bypass; CVA: 
cerebrovascular accident; IABP: intra-aortic balloon pump; RRT: renal replacement therapy; IR: incomplete revascularization. 
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Supplementary Table 1. Absolute standardized mean difference (ASMD) for each variable among groups comparison in the unweighted 
population   
Variable Group 1 Group 2 ASMD  Group 1 Group 2 ASMD 
Age SAONCAB MAONCAB 110%  MAONCAB MAOPCAB 42% 
Female  SAONCAB MAONCAB 25%  MAONCAB MAOPCAB 7% 
NYHA III-IV  SAONCAB MAONCAB 7%  MAONCAB MAOPCAB 11% 
CCS III-IV  SAONCAB MAONCAB 14%  MAONCAB MAOPCAB 7% 
MI within 30 days  SAONCAB MAONCAB 18%  MAONCAB MAOPCAB 18% 
PCI  SAONCAB MAONCAB 7%  MAONCAB MAOPCAB 15% 
DM orally treated  SAONCAB MAONCAB 16%  MAONCAB MAOPCAB 11% 
DM on insulin  SAONCAB MAONCAB 9%  MAONCAB MAOPCAB 2% 
Current smoking  SAONCAB MAONCAB 17%  MAONCAB MAOPCAB 8% 
Creatinine≥200mmol/l  SAONCAB MAONCAB 14%  MAONCAB MAOPCAB 0% 
COPD  SAONCAB MAONCAB 18%  MAONCAB MAOPCAB 5% 
CVA  SAONCAB MAONCAB 7%  MAONCAB MAOPCAB 2% 
PVD  SAONCAB MAONCAB 14%  MAONCAB MAOPCAB 2% 
Atrial fibrillation   SAONCAB MAONCAB 8%  MAONCAB MAOPCAB 0% 
3-vessel disease SAONCAB MAONCAB 19%  MAONCAB MAOPCAB 11% 
Left main disease SAONCAB MAONCAB 12%  MAONCAB MAOPCAB 18% 
LVEF between 30-49%  SAONCAB MAONCAB 15%  MAONCAB MAOPCAB 2% 
LVEF ≤30% SAONCAB MAONCAB 15%  MAONCAB MAOPCAB 6% 
Cardiogenic shock  SAONCAB MAONCAB 11%  MAONCAB MAOPCAB 1% 
Preoperative IABP  SAONCAB MAONCAB 12%  MAONCAB MAOPCAB 2% 
Non-elective admission  SAONCAB MAONCAB 15%  MAONCAB MAOPCAB 1% 
Emergent/salvage  SAONCAB MAONCAB 10%  MAONCAB MAOPCAB 1% 
BMI  SAONCAB MAONCAB 12%  MAONCAB MAOPCAB 7% 
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Year of surgery SAONCAB MAONCAB 44%  MAONCAB MAOPCAB 77% 
Age SAONCAB MAOPCAB 68%  MAONCAB SAOPCAB 121% 
Female  SAONCAB MAOPCAB 18%  MAONCAB SAOPCAB 26% 
NYHA III-IV  SAONCAB MAOPCAB 18%  MAONCAB SAOPCAB 7% 
CCS III-IV  SAONCAB MAOPCAB 21%  MAONCAB SAOPCAB 12% 
MI within 30 days  SAONCAB MAOPCAB 0%  MAONCAB SAOPCAB 26% 
PCI  SAONCAB MAOPCAB 8%  MAONCAB SAOPCAB 15% 
DM orally treated  SAONCAB MAOPCAB 5%  MAONCAB SAOPCAB 18% 
DM on insulin  SAONCAB MAOPCAB 7%  MAONCAB SAOPCAB 12% 
Current smoking  SAONCAB MAOPCAB 9%  MAONCAB SAOPCAB 18% 
Creatinine≥200mmol/l  SAONCAB MAOPCAB 14%  MAONCAB SAOPCAB 16% 
COPD  SAONCAB MAOPCAB 13%  MAONCAB SAOPCAB 20% 
CVA  SAONCAB MAOPCAB 10%  MAONCAB SAOPCAB 8% 
PVD  SAONCAB MAOPCAB 12%  MAONCAB SAOPCAB 15% 
Atrial fibrillation   SAONCAB MAOPCAB 8%  MAONCAB SAOPCAB 8% 
3-vessel disease SAONCAB MAOPCAB 30%  MAONCAB SAOPCAB 7% 
Left main disease SAONCAB MAOPCAB 5%  MAONCAB SAOPCAB 21% 
LVEF between 30-49%  SAONCAB MAOPCAB 17%  MAONCAB SAOPCAB 15% 
LVEF ≤30% SAONCAB MAOPCAB 21%  MAONCAB SAOPCAB 11% 
Cardiogenic shock  SAONCAB MAOPCAB 10%  MAONCAB SAOPCAB 4% 
Preoperative IABP  SAONCAB MAOPCAB 10%  MAONCAB SAOPCAB 11% 
Non-elective admission  SAONCAB MAOPCAB 16%  MAONCAB SAOPCAB 13% 
Emergent/salvage  SAONCAB MAOPCAB 9%  MAONCAB SAOPCAB 6% 
BMI  SAONCAB MAOPCAB 19%  MAONCAB SAOPCAB 2% 
Year of surgery SAONCAB MAOPCAB 33%  MAONCAB SAOPCAB 92% 
Age SAONCAB SAOPCAB 12%  MAOPCAB SAOPCAB 79% 
Female  SAONCAB SAOPCAB 1%  MAOPCAB SAOPCAB 18% 
NYHA III-IV  SAONCAB SAOPCAB 14%  MAOPCAB SAOPCAB 4% 
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CCS III-IV  SAONCAB SAOPCAB 1%  MAOPCAB SAOPCAB 20% 
MI within 30 days  SAONCAB SAOPCAB 8%  MAOPCAB SAOPCAB 8% 
PCI  SAONCAB SAOPCAB 8%  MAOPCAB SAOPCAB 0% 
DM orally treated  SAONCAB SAOPCAB 2%  MAOPCAB SAOPCAB 7% 
DM on insulin  SAONCAB SAOPCAB 3%  MAOPCAB SAOPCAB 10% 
Current smoking  SAONCAB SAOPCAB 1%  MAOPCAB SAOPCAB 10% 
Creatinine≥200mmol/l  SAONCAB SAOPCAB 2%  MAOPCAB SAOPCAB 16% 
COPD  SAONCAB SAOPCAB 2%  MAOPCAB SAOPCAB 15% 
CVA  SAONCAB SAOPCAB 1%  MAOPCAB SAOPCAB 11% 
PVD  SAONCAB SAOPCAB 1%  MAOPCAB SAOPCAB 13% 
Atrial fibrillation   SAONCAB SAOPCAB 0%  MAOPCAB SAOPCAB 8% 
3-vessel disease SAONCAB SAOPCAB 26%  MAOPCAB SAOPCAB 4% 
Left main disease SAONCAB SAOPCAB 9%  MAOPCAB SAOPCAB 3% 
LVEF between 30-49%  SAONCAB SAOPCAB 0%  MAOPCAB SAOPCAB 17% 
LVEF ≤30% SAONCAB SAOPCAB 5%  MAOPCAB SAOPCAB 16% 
Cardiogenic shock  SAONCAB SAOPCAB 7%  MAOPCAB SAOPCAB 3% 
Preoperative IABP  SAONCAB SAOPCAB 1%  MAOPCAB SAOPCAB 9% 
Non-elective admission  SAONCAB SAOPCAB 1%  MAOPCAB SAOPCAB 14% 
Emergent/salvage  SAONCAB SAOPCAB 4%  MAOPCAB SAOPCAB 4% 
BMI  SAONCAB SAOPCAB 10%  MAOPCAB SAOPCAB 9% 
Year of surgery SAONCAB SAOPCAB 48%  MAOPCAB SAOPCAB 15% 
SA: single Artery; MA: multiple arteries; OPCAB: off-pump coronary artery bypass; ONCAB: on-pump coronary artery bypass; NYHA: New York Heart Association: CCS: 
Scandinavian cardiovascular Society; MI: myocardial infarction; PCI: percutaneous coronary intervention; DM: diabetes mellitus; COPD: chronic obstructive pulmonary 
disease; CVA: cerebrovascular accident;  PVD: peripheral vascular disease; LVEF: left ventricular ejection fraction; IABP: intra-aortic balloon pump; BMI: body mass index; 
ASMD: absolute standardized mean difference 
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Supplementary Figure 2. Absolute standardized mean difference (ASMD) for each variable among groups comparison after inverse Propensity 
score weighting   
Variable Group 1 Group 2 ASMD  Group 1 Group 2 ASMD 
Age SAONCAB MAONCAB 11%  MAONCAB MAOPCAB 1% 
Female  SAONCAB MAONCAB 6%  MAONCAB MAOPCAB 2% 
NYHA III-IV  SAONCAB MAONCAB 0%  MAONCAB MAOPCAB 4% 
CCS III-IV  SAONCAB MAONCAB 4%  MAONCAB MAOPCAB 8% 
MI within 30 days  SAONCAB MAONCAB 4%  MAONCAB MAOPCAB 4% 
PCI  SAONCAB MAONCAB 0%  MAONCAB MAOPCAB 4% 
DM orally treated  SAONCAB MAONCAB 1%  MAONCAB MAOPCAB 2% 
DM on insulin  SAONCAB MAONCAB 10%  MAONCAB MAOPCAB 6% 
Current smoking  SAONCAB MAONCAB 5%  MAONCAB MAOPCAB 0% 
Creatinine≥200mmol/l  SAONCAB MAONCAB 10%  MAONCAB MAOPCAB 4% 
COPD  SAONCAB MAONCAB 0%  MAONCAB MAOPCAB 5% 
CVA  SAONCAB MAONCAB 2%  MAONCAB MAOPCAB 10% 
PVD  SAONCAB MAONCAB 5%  MAONCAB MAOPCAB 1% 
Atrial fibrillation   SAONCAB MAONCAB 4%  MAONCAB MAOPCAB 4% 
3-vessel disease SAONCAB MAONCAB 6%  MAONCAB MAOPCAB 2% 
Left main disease SAONCAB MAONCAB 0%  MAONCAB MAOPCAB 1% 
LVEF between 30-49%  SAONCAB MAONCAB 3%  MAONCAB MAOPCAB 8% 
LVEF ≤30% SAONCAB MAONCAB 7%  MAONCAB MAOPCAB 16% 
Cardiogenic shock  SAONCAB MAONCAB 7%  MAONCAB MAOPCAB 2% 
Preoperative IABP  SAONCAB MAONCAB 9%  MAONCAB MAOPCAB 4% 
Non-elective admission  SAONCAB MAONCAB 1%  MAONCAB MAOPCAB 4% 
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Emergent/salvage  SAONCAB MAONCAB 5%  MAONCAB MAOPCAB 1% 
BMI  SAONCAB MAONCAB 5%  MAONCAB MAOPCAB 3% 
Year of surgery SAONCAB MAONCAB 5%  MAONCAB MAOPCAB 13% 
Age SAONCAB MAOPCAB 10%  MAONCAB SAOPCAB 14% 
Female  SAONCAB MAOPCAB 4%  MAONCAB SAOPCAB 4% 
NYHA III-IV  SAONCAB MAOPCAB 4%  MAONCAB SAOPCAB 2% 
CCS III-IV  SAONCAB MAOPCAB 5%  MAONCAB SAOPCAB 3% 
MI within 30 days  SAONCAB MAOPCAB 0%  MAONCAB SAOPCAB 3% 
PCI  SAONCAB MAOPCAB 4%  MAONCAB SAOPCAB 0% 
DM orally treated  SAONCAB MAOPCAB 0%  MAONCAB SAOPCAB 2% 
DM on insulin  SAONCAB MAOPCAB 4%  MAONCAB SAOPCAB 9% 
Current smoking  SAONCAB MAOPCAB 5%  MAONCAB SAOPCAB 3% 
Creatinine≥200mmol/l  SAONCAB MAOPCAB 6%  MAONCAB SAOPCAB 9% 
COPD  SAONCAB MAOPCAB 5%  MAONCAB SAOPCAB 1% 
CVA  SAONCAB MAOPCAB 8%  MAONCAB SAOPCAB 1% 
PVD  SAONCAB MAOPCAB 7%  MAONCAB SAOPCAB 5% 
Atrial fibrillation   SAONCAB MAOPCAB 0%  MAONCAB SAOPCAB 6% 
3-vessel disease SAONCAB MAOPCAB 8%  MAONCAB SAOPCAB 0% 
Left main disease SAONCAB MAOPCAB 1%  MAONCAB SAOPCAB 1% 
LVEF between 30-49%  SAONCAB MAOPCAB 6%  MAONCAB SAOPCAB 4% 
LVEF ≤30% SAONCAB MAOPCAB 9%  MAONCAB SAOPCAB 8% 
Cardiogenic shock  SAONCAB MAOPCAB 5%  MAONCAB SAOPCAB 4% 
Preoperative IABP  SAONCAB MAOPCAB 5%  MAONCAB SAOPCAB 9% 
Non-elective admission  SAONCAB MAOPCAB 5%  MAONCAB SAOPCAB 1% 
Emergent/salvage  SAONCAB MAOPCAB 6%  MAONCAB SAOPCAB 2% 
BMI  SAONCAB MAOPCAB 8%  MAONCAB SAOPCAB 5% 
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Year of surgery SAONCAB MAOPCAB 8%  MAONCAB SAOPCAB 13% 
Age SAONCAB SAOPCAB 3%  MAOPCAB SAOPCAB 13% 
Female  SAONCAB SAOPCAB 2%  MAOPCAB SAOPCAB 2% 
NYHA III-IV  SAONCAB SAOPCAB 2%  MAOPCAB SAOPCAB 2% 
CCS III-IV  SAONCAB SAOPCAB 1%  MAOPCAB SAOPCAB 6% 
MI within 30 days  SAONCAB SAOPCAB 1%  MAOPCAB SAOPCAB 1% 
PCI  SAONCAB SAOPCAB 0%  MAOPCAB SAOPCAB 4% 
DM orally treated  SAONCAB SAOPCAB 1%  MAOPCAB SAOPCAB 0% 
DM on insulin  SAONCAB SAOPCAB 0%  MAOPCAB SAOPCAB 4% 
Current smoking  SAONCAB SAOPCAB 1%  MAOPCAB SAOPCAB 3% 
Creatinine≥200mmol/l  SAONCAB SAOPCAB 1%  MAOPCAB SAOPCAB 6% 
COPD  SAONCAB SAOPCAB 1%  MAOPCAB SAOPCAB 4% 
CVA  SAONCAB SAOPCAB 1%  MAOPCAB SAOPCAB 9% 
PVD  SAONCAB SAOPCAB 0%  MAOPCAB SAOPCAB 6% 
Atrial fibrillation   SAONCAB SAOPCAB 2%  MAOPCAB SAOPCAB 1% 
3-vessel disease SAONCAB SAOPCAB 6%  MAOPCAB SAOPCAB 2% 
Left main disease SAONCAB SAOPCAB 1%  MAOPCAB SAOPCAB 2% 
LVEF between 30-49%  SAONCAB SAOPCAB 1%  MAOPCAB SAOPCAB 5% 
LVEF ≤30% SAONCAB SAOPCAB 2%  MAOPCAB SAOPCAB 8% 
Cardiogenic shock  SAONCAB SAOPCAB 3%  MAOPCAB SAOPCAB 2% 
Preoperative IABP  SAONCAB SAOPCAB 0%  MAOPCAB SAOPCAB 5% 
Non-elective admission  SAONCAB SAOPCAB 0%  MAOPCAB SAOPCAB 6% 
Emergent/salvage  SAONCAB SAOPCAB 3%  MAOPCAB SAOPCAB 3% 
BMI  SAONCAB SAOPCAB 0%  MAOPCAB SAOPCAB 8% 
Year of surgery SAONCAB SAOPCAB 8%  MAOPCAB SAOPCAB 1% 
SA: single Artery; MA: multiple arteries; OPCAB: off-pump coronary artery bypass; ONCAB: on-pump coronary artery bypass; NYHA: New York Heart Association: CCS: 
Scandinavian cardiovascular Society; MI: myocardial infarction; PCI: percutaneous coronary intervention; DM: diabetes mellitus; COPD: chronic obstructive pulmonary 
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disease; CVA: cerebrovascular accident;  PVD: peripheral vascular disease; LVEF: left ventricular ejection fraction; IABP: intra-aortic balloon pump; BMI: body mass index; 
ASMD: absolute standardized mean difference 
 
Figure Legends.  
Figure 1. Number of multiple arterial (MA) and single arterial (SA) off-pump coronary artery bypass (OPCAB) and on pump coronary artery 
bypass (ONCAB) surgery during the study period.  
Figure 2. Survival rate in the unweighted (left) and propensity score weighted (right) multiple arterial (MA) and single arterial (SA) off-
pump coronary artery bypass (OPCAB) and on pump coronary artery bypass (ONCAB) surgery groups (± standard errors at 5,10 and 
15 years are reported for each propensity score weighted group).  
Supplementary Figure 1. Change in maximum absolute standardized mean differences before and after propensity score weighting.   
Supplementary Figure 2. Survival rate in the unweighted multiple arterial (MA) and single arterial (SA) off-pump coronary artery bypass 
(OPCAB) and on pump coronary artery bypass (ONCAB) surgery groups according to completeness of revascularization.  
Supplementary Figure 3. Survival rate in the unweighted multiple arterial (MA) plus saphenous vein (SV), total arterial (TA) and single 
arterial (SA) off-pump coronary artery bypass (OPCAB) and on pump coronary artery bypass (ONCAB) surgery groups.  
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Supplementary Figure 4. Survival rate in the unweighted multiple arterial (MA) and single arterial (SA) off-pump coronary artery bypass 
(OPCAB) and on pump coronary artery bypass (ONCAB) surgery groups across eras of surgery.  
Central picture: Survival rate in the propensity score weighted multiple arterial (MA) and single arterial (SA) off-pump coronary artery 
bypass (OPCAB) and on pump coronary artery bypass (ONCAB) surgery groups. (±standard errors at 5,10 and 15 years are reported 
for each propensity score weighted group).  
Video 1. Use of the Radial Artery during off-pump coronary artery bypass  
 
